
Mainz BioMed (NASDAQ: MYNZ)
@MainzBioMed
Mainz BioMed (NASDAQ: $MYNZ) develops market-ready molecular genetic diagnostic solutions for life-threatening conditions, such as #colorectal cancer.
Może Ci się spodobać
$MYNZ launches its updated ColoAlert version for CRC screening, featuring a new DNA stabilizing buffer which significantly enhances the lab efficiency. Faster results and fewer retests! #stockmarketnews #investing mainzbiomed.com/mainz-biomed-l…

📰Mainz Biomed reports topline feasibility results for its pancreatic cancer biomarker panel: 100% sensitivity, 95% specificity. Proprietary biomarkers + Liquid Biosciences’ algorithm validate a high-potential early detection platform. More information: mainzbiomed.com/mainz-biomed-r……

A key moment in colorectal cancer research! On Oct 3, Mainz Biomed will be at the WEO CRC Screening Committee Meeting in Berlin. Dr. Lena Krammes will present findings from the eAArly DETECT study, showing how RNA-based stool testing can detect cancer early. Read more:…

Commercial launch achieved: Mainz Biomed rolls out ColoAlert® in Switzerland and keeps the eAArly DETECT 2 study on track. Read more here: mainzbiomed.com/mainz-biomed-a… #Cancer #CancerAwareness #healthTech #Innovation #Research #Health #StockMarket #Growth #MarketAlert $MYNZ…

Big news: ColoAlert® has been approved in the United Kingdom! A step forward for early colorectal cancer detection — and for making innovative diagnostics more accessible. More information: mainzbiomed.com/mainz-biomed-a… #StockMarket #investors #Growth #Innovation #healthcare…

ColoAlert® has received Swissmedic approval ✅ Thanks to our partnership with labor team w ag, our non-invasive, highly sensitive test is now available in Switzerland — to change the reality that only 50% of eligible adults get screened for colorectal cancer. Read more here:…

🤝We’re partnering with CARE, a German diagnostics company working with 15+ health insurers to provide online colorectal cancer screening using the FIT test. Together, we’re expanding access to advanced early detection with ColoAlert® #stocks #investors #stockmarkets…

Mainz Biomed made strong H1 2025 progress in early cancer detection: Launched eAArly DETECT 2 (2,000 pts), setting up 2026 FDA CRC trial ColoAlert® launched in Switzerland (labor team w ag), expanded in UK (EDX Medical) Advanced pancreatic cancer program: licensed Liquid…

Big news! Mainz Biomed secured public funding from Investitions- und Strukturbank Rheinland-Pfalz (ISB), covering 50% of costs to advance their non-invasive blood test for early pancreatic cancer detection. Learn more: mainzbiomed.com/mainz-biomed-s… #Cancer #CancerResearch…

We’ve begun the feasibility phase of PancAlert, validating a biomarker panel with 95% sensitivity and 98% specificity in partnership with Crown bioscience. This step tests assay accuracy, reproducibility, and risk stratification—key for FDA. Learn more: mainzbiomed.com/mainz-biomed-i……

eAArly DETECT 2 Clinical Study Update 🗓️Interim read out by Summer 2025! Goal: Validate next-gen test for early colon cancer detection. 🔬 Detecting polyps & precancerous adenomas. 🗓 Top-line results: Q4 2025 🇺🇸 Potential U.S. trial: 2026 Stay tuned and learn more here:…

Mainz Biomed and EDX Medical have joined forces. 🤝A strategic partnership to bring advanced molecular diagnostics to the UK Learn more: mainzbiomed.com/mainz-biomed-e… #stocks #investors #stockmarkets #UnitedKingdom #CancerPrevention #Cancer #Health #Medical $Nasdaq $MYNZ

Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval Read the full update here: mainzbiomed.com/mainz-biomed-p… $MYNZ #INVESTING #NASDAQ #GROWTH

Mainz Biomed 2024 Highlights 📈 Lab network revenue increased by 33% year over year. 📉Operating loss decreased by 30% and net loss by 18%. 🤝 New partnerships with Thermo Fisher, Quest Diagnostics, and Liquid Biosciences 💡Key moments: 📊ASCO 2024: Key colorectal cancer data…

Mainz Biomed enrolls the first patient in its eAArly DETECT 2 study. 🔬 2,000+ average-risk patients ✅ Validates previous results 🛡️ Aims to shift from CRC screening to prevention 🇺🇸 Supports future U.S. programs 📅 Top-line results expected Q4 2025 Learn more:…

Mainz Biomed & Liquid Biosciences announce groundbreaking discovery of mRNA biomarkers for blood-based detection of #pancreatic cancer. 🧪Discovery analysis: 95% sensitivity AND 98% specificity 📄 Mainz Biomed signs exclusive license & option agreement for the biomarker…

This March, we stand against colorectal cancer. Early detection saves lives. With accessible at-home testing, we help more people get tested — because every life is worth protecting. Learn more: mainzbiomed.com/colorectal-can… #Cancer #CancerAwareness #cancerai #Science #innovation…

Saving lives through early detection! 🇨🇭 Mainz Biomed partners with Labor Team W AG to introduce ColoAlert®—a non-invasive, DNA-based colorectal cancer screening test— in Switzerland. Early detection saves lives. Easier screening = More lives saved. Learn more :…

Preventing one of the deadliest preventable cancers! In partnership with GANZIMMUN Diagnostics, our enhanced ColoAlert test is now available across Germany for early detection. Learn more: mainzbiomed.com/mainz-biomed-a… $MYNZ #StockMarket #investoropportunity #Investor #Innovation…

Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements Learn more: mainzbiomed.com/mainz-biomed-n… #StockMarkets #investing #growthstock #Growth #investor #investoropportunity #NASDAQ #CancerResearch $MYNZ

United States Trendy
- 1. Good Sunday 46.5K posts
- 2. Discussing Web3 N/A
- 3. #sundayvibes 4,116 posts
- 4. Auburn 47.2K posts
- 5. Wordle 1,576 X N/A
- 6. MACROHARD 8,202 posts
- 7. Gilligan's Island 5,224 posts
- 8. #SEVENTEEN_NEW_IN_TACOMA 39.4K posts
- 9. #MakeOffer 20.6K posts
- 10. QUICK TRADE 2,178 posts
- 11. Kirby 24.8K posts
- 12. #SVT_TOUR_NEW_ 31.4K posts
- 13. FDV 5min 2,207 posts
- 14. Utah 25.4K posts
- 15. #SVT_WORLDTOUR 28.7K posts
- 16. Market Cap Surges N/A
- 17. Dissidia 7,317 posts
- 18. Whale - Buy 1,825 posts
- 19. Boots 51.3K posts
- 20. Arizona 41K posts
Something went wrong.
Something went wrong.